SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-170556"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-170556" > Effects of dapaglif...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004535naa a2200409 4500
001oai:DiVA.org:uu-170556
003SwePub
008120312s2012 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:124242358
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1705562 URI
0247 a https://doi.org/10.1210/jc.2011-22602 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1242423582 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Bolinder, Janu Karolinska Institutet4 aut
2451 0a Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
264 1b The Endocrine Society,c 2012
338 a print2 rdacarrier
520 a Context:Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding.Objectives:Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components.Design and Setting:This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries.Patients:Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin.Intervention:Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk.Main Outcome Measures:Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated.Results:At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, −2.08 kg [95% confidence interval (CI) = −2.84 to −1.31; P < 0.0001]; waist circumference, −1.52 cm (95% CI = −2.74 to −0.31; P = 0.0143); FM, −1.48 kg (95% CI = −2.22 to −0.74; P = 0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI = 15.5 to 36.7; P < 0.0001); VAT, −258.4 cm3 (95% CI = −448.1 to −68.6; nominal P = 0.0084); SAT, −184.9 cm3 (95% CI = −359.7 to −10.1; nominal P = 0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%.Conclusions:Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
7001 a Ljunggren, Östenu Uppsala universitet,Metabola bensjukdomar4 aut0 (Swepub:uu)osteljun
7001 a Kullberg, Joelu Uppsala universitet,Enheten för radiologi4 aut0 (Swepub:uu)jokul377
7001 a Johansson, Larsu Uppsala universitet,Enheten för radiologi4 aut0 (Swepub:uu)larsjoha
7001 a Wilding, John4 aut
7001 a Langkilde, Anna Maria4 aut
7001 a Sugg, Jennifer4 aut
7001 a Parikh, Shamik4 aut
7102 a Karolinska Institutetb Metabola bensjukdomar4 org
7730 t Journal of Clinical Endocrinology and Metabolismd : The Endocrine Societyg 97:3, s. 1020-1031q 97:3<1020-1031x 0021-972Xx 1945-7197
8564 u https://academic.oup.com/jcem/article-pdf/97/3/1020/10416511/jcem1020.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-170556
8564 8u https://doi.org/10.1210/jc.2011-2260
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:124242358

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy